ACTICOR BIOTECH news, videos and press releases
For more news please use our advanced search feature.
ACTICOR BIOTECH - More news...
ACTICOR BIOTECH - More news...
- The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack
- Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke
- Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke
- ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of July 31, 2023
- Acticor Biotech: Half-Year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
- ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of June 30, 2023
- Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of May 31, 2023
- Acticor Biotech: Progress in Discussions with EU and US Regulatory Agencies
- Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research
- ACTICOR BIOTECH: Report of the Combined General Meeting of May 12, 2023
- ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2023
- ACTICOR BIOTECH: Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023
- Acticor Biotech: Disclosure of The Total Number of Voting Rights and Shares as of March 31, 2023
- Acticor Biotech Publishes Its 2022 Annual Results and Provides an Update on Its Clinical Progress
- Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of February 28, 2023
- ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2023
- Acticor Biotech Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director
- Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies
- Update on Acticor Biotech's Clinical Developments With Glenzocimab in the Treatment of Cardiovascular Emergencies
- Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2022
- Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
- Acticor Biotech Provides an Update on the Us Regulatory Discussion with the FDA
- Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of November 30, 2022
- Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke
- Acticor Biotech Announces Its Financial Agenda for The 1st Half of 2023
- Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
- Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
- Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of October 31, 2022
- Acticor Biotech Announces Its 2022 Half-year Financial Results and Update on Its Clinical Progress
- Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of September 30, 2022
